KRAS Mouse Monoclonal Antibody [A8E5]

About this product

The K-Ras protein is a GTPase, a class of enzymes which convert the nucleotide guanosine triphosphate (GTP) into guanosine diphosphate (GDP). In this way the K-Ras protein acts like a switch that is turned on and off by the GTP and GDP molecules. To transmit signals, it must be turned on by attaching (binding) to a molecule of GTP. The K-Ras protein is turned off (inactivated) when it converts the GTP to GDP. When the protein is bound to GDP, it does not relay signals to the cell's nucleus. Several germline KRAS mutations have been found to be associated with Noonan syndrome and cardio-facio-cutaneous syndrome. Somatic KRAS mutations are found at high rates in leukemias, colorectal cancer, pancreatic cancer and lung cancer. KRAS mutations are more commonly observed in cecal cancers than colorectal cancers located in any other places from ascending colon to rectum. KRAS gene can also be amplified in colorectal cancer. Tumors or cell lines harboring this genetic lesion are not responsive to EGFR inhibitors. Although KRAS amplification is an infrequent event in colorectal cancer, it might be responsible for precluding response to anti-EGFR treatment in some patients. Amplification of wild-type Kras has also been observed in ovarian, gastric, uterine, and lung cancers. Driver mutations in KRAS underlie the pathogenesis of up to 20% of human cancers. Hence KRAS is an attractive drug target, however lack of obvious binding sites has hindered pharmaceutical development. One potential drug interaction site is where GTP/GDP binds. However, due to the extraordinarily high affinity of GTP/GDP for this site, it is unlikely that drug-like small molecule inhibitors could compete with GTP/GDP binding. Other than where GTP/GDP binds, there are no obvious high affinity binding sites for small molecules.

Specifications

Catalog number

HA601059

Size / count

100 µL

Dry ice

No

Hazardous

No

Discontinued

No

CAS Number

9007-83-4

Product Name Alternative

c Ki ras2 antibody c Kirsten ras protein antibody c-K-ras antibody c-Ki-ras antibody Cellular c Ki ras2 proto oncogene antibody Cellular transforming proto oncogene antibody CFC2 antibody cK Ras antibody GTPase KRas antibody K RAS p21 protein antibody K RAS2A antibody K RAS2B antibody K RAS4A antibody K RAS4B antibody K-Ras 2 antibody KI RAS antibody Ki-Ras antibody KIRSTEN MURINE SARCOMA VIRUS 2 antibody Kirsten rat sarcoma 2 viral (v Ki ras2) oncogene homolog antibody Kirsten rat sarcoma viral oncogene homolog antibody KRAS antibody KRAS proto oncogene, GTPase antibody KRAS1 antibody KRAS2 antibody N-terminally processed antibody NS antibody NS3 antibody Oncogene KRAS2 antibody p21ras antibody PR310 c K ras oncogene antibody PR310 cK ras oncogene antibody RALD antibody RASK_HUMAN antibody RASK2 antibody Transforming protein p21 antibody v Ki ras2 Kirsten rat sarcoma 2 viral oncogene homolog antibody v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody

Abbreviation

GTPase KRas K-Ras 2 Ki-Ras c-K-ras c-Ki-ras GTPase KRas, N-terminally processed KRAS KRAS2 RASK2

Swiss Prot

P01116 Human, P32883 Mouse, P08644 Rat

Cellular Locus

Cell membrane. Cytoplasm.

Host

Mouse

Species Reactivity

Human, Mouse, Rat

Immunogen

Recombinant protein within human KRAS aa 2-186.

Isotype

IgG1

Conjugation

Non-conjugated

Type

Mouse monoclonal Antibody

Applications

WB, IF-Cell, IHC-P, FC

Positive Control

Rat brain tissue lysate, PC-12 cell lysate, human kidney tissue lysate, Jurkat cell lysate, NIH/3T3, human lung carcinoma tissue, Hela.

Concentration

1 mg/mL

Dilution

WB: 1:1,000;IF-Cell: 1:100;IHC-P: 1:1100;FC: 1:500-1:1,000

Purity

Protein A affinity purified.

Form

Liquid

Buffer

PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Molecular Weight

Predicted band size: 21 kDa

Storage Conditions

Store at +4°C after thawing. Aliquot store at -20°C. Avoid repeated freeze/thaw cycles.

Recombinant Antibody

No